4-(2-Tetrahydropyranyloxy)-1-cyclohexanol | 64230-40-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-Tetrahydropyranyloxy)-1-cyclohexanol
• 英文别名: 4-(tetrahydropyran-2-yloxy)cyclohexanol；4-(tetrahydro-2H-pyran-2-yloxy)cyclohexanol；4-(oxan-2-yloxy)cyclohexan-1-ol
• CAS: 64230-40-6
• 化学式: C₁₁H₂₀O₃
• 分子量: 200.278
• InChiKey: CFWFCOFXUZXFDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-Tetrahydropyranyloxy)-1-cyclohexanol 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-(四氢-2H-吡喃-2-基氧基)环己酮
  参考文献：
  名称：

  4-[3-(三甲基甲硅烷基)prop-1-en-1-yl]环己烷甲醛分子内环化失去甲酰碳

  摘要：

  在稀四氢呋喃中用四丁基氟化铵处理顺式和反式 4-[3-(三甲基甲硅烷基)prop-1-en-1-yl] 环己烷甲醛 (2a 和 2b)，得到 7-乙烯基双环 [2.2.1] 庚烷-1- ol (3)，从 4-[3-(三甲基甲硅烷基)prop-1-en-1-yl] 环己酮 (1) 获得的相同产物。发现 2a、b 到 1 的氧化去甲酰化在环化成 3 之前在碱性条件下发生。还表明烯丙基硅烷与羰基的环化不通过重叠构象进行。

  DOI：

  10.1246/bcsj.71.1639
• 作为产物：
  描述：

  3,4-二氢-2H-吡喃 、 1,4-环己二醇 在 lithium trifluoromethanesulfonate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 5.5h， 以93%的产率得到4-(2-Tetrahydropyranyloxy)-1-cyclohexanol
  参考文献：
  名称：

  在轻度和中性反应条件下，三氟甲磺酸锂（LiOTf）催化醇和酚的高效和化学选择性四氢吡喃基化

  摘要：

  在DHP和催化量的三氟甲烷磺酸锂（LiOTf）的存在下，在基本中性的反应条件下，将不同类型的醇和酚有效地转化为相应的THP醚。该方法对对称二醇的单四氢吡喃基化反应也显示出良好的化学选择性。

  DOI：

  10.1016/s0040-4039(02)00892-4

文献信息

• Highly selective monotetrahydropyranylation of symmetrical diols catalysed by a strongly acidic ion-exchange resin
  作者：Takeshi Nishiguchi、Masahumi Kuroda、Masahiko Saitoh、Akiko Nishida、Shizuo Fujisaki

  DOI：10.1039/c39950002491

  日期：——

  Several primary and secondary symmetrical diols, ranging from propane-1,3-diol to decane-1,10-diol, are selectively monoprotected by monotetrahydropyranyl ether formation catalysed by a strongly acidic ion-exchange resin (Dowex 50w × 2, 50–100 mesh) in a 3,4-dihydro-2H-pyran-hydrocarbon mixture.

  几个选自丙二醇-1,3至癸二醇-1,10的主、次对称二醇，在强酸性离子交换树脂（Dowex 50w× 2，50-100目）催化下，以3,4-二氢-2H-吡喃-烃混合物为介质，发生单四氢吡喃醚选择性单保护反应。
• Rho kinase inhibitors
  申请人：——

  公开号：US20040138286A1

  公开（公告）日：2004-07-15

  A compound represented by the formula (1): 1 wherein R 1 —X— indicates that 1 to 4 R 1 —X— groups are present which may be the same or different, the ring A is a saturated or unsaturated 5-membered heterocyclic ring, X is a single bond, a group represented by the formula: —N(R 3 )—, —O— or —S—, or the like. R 1 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, R 2 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, and R 3 is a hydrogen atom, a substituted or unsubstituted alkyl group, or the like; a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is a useful compound as a therapeutic agent for diseases for which Rho kinase is responsible.

  化合物的化学式为（1）：1，其中R1—X—表示存在1到4个R1—X—基团，可以相同也可以不同，环A是饱和或不饱和的5元杂环，X是单键，一个由式子表示的基团：—N（R3）—，—O—或—S—等。R1是氢原子，卤素原子，硝基，羧基，取代或未取代的烷基或类似物，R2是氢原子，卤素原子，硝基，羧基，取代或未取代的烷基或类似物，R3是氢原子，取代或未取代的烷基或类似物；该化合物的前药或药物可接受的盐是治疗Rho激酶相关疾病的有用化合物。
• HETEROMONOCYCLIC COMPOUND AND USE THEREOF
  申请人：Kuroita Takanobu

  公开号：US20080207654A1

  公开（公告）日：2008-08-28

  A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of circulatory diseases, metabolic diseases and/or central nervous system diseases.

  化合物的化学式为(I)，其中R1为氧代基，═N—R或类似基团；式中的基团表示为：其中R2为式中的基团；R3和R4分别为H，或C1-C6烷基，C3-C6环烷基，C1-C6烷氧基，C1-C6烷基氨基，二(C1-C6)烷基氨基或C1-C6烷基硫基，每个基团均可选地被取代；R5为H，或C1-C6烷基，C2-C6烯基，环状基团，每个基团均可选地被取代，—CO—R8或—O—R8′，或其盐。本发明的化合物可用作预防或治疗循环系统疾病、代谢性疾病和/或中枢神经系统疾病的药物。
• Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07998968B2

  公开（公告）日：2011-08-16

  A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. For example, the compound may be substituted pyrimidines and pharmaceutical compositions of the formula (I) where X=—CR3; X1=—CR2 or —NR2; and X2=—CR5 or —NR5. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.

  化合物的化学式为(I)：其中R1是氧代基，═N—R或类似的基团；由式子表示的基团：是由式子表示的基团：R2是由式子表示的基团：R3和R4分别是H，或C1-C6烷基，C3-C6环烷基，C1-C6烷氧基，C1-C6烷基氨基，二(C1-C6)烷基氨基或C1-C6烷基硫基，每个基团都可以选择性地被取代；而R5是H，或C1-C6烷基，C2-C6烯基，环状基团，每个基团都可以选择性地被取代，—CO—R8或—O—R8′，或其盐。例如，该化合物可以是取代的嘧啶，并且具有化学式(I)的制药组合物，其中X=—CR3；X1=—CR2或—NR2；X2=—CR5或—NR5。本发明的化合物可用作预防或治疗心血管疾病、代谢性疾病和/或中枢神经系统疾病的药物。
• Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07803940B2

  公开（公告）日：2010-09-28

  A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.

  化合物的化学式为(I)，其中R1代表氧代基，═N—R或类似基团；式中代表的基团为：R2代表式中代表的基团；R3和R4分别代表氢、C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷基氨基、双(C1-C6)烷基氨基或C1-C6烷基硫基，每个基团都可以选择性地被取代；R5代表氢、C1-C6烷基、C2-C6烯基、环状基团，每个基团都可以选择性地被取代，—CO—R8或—O—R8′，或其盐。本发明的化合物可用作预防或治疗心血管疾病、代谢性疾病和/或中枢神经系统疾病的药物。